Physician profile
Rohan Verma
NPI 1619362548
$2,284.89
in general payments reported to CMS, 2019-2025
12 companies · $953 in 2025
The $953 reported for 2025 was more than what 77% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.57 · 2022: $42.90 · 2023: $360 · 2024: $867 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $763.93 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $455.53 | 2019-2024 | Clareon, Wavelight Refractive Suite |
| Tarsus Pharmaceuticals, INC. | $301.18 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $216.61 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $189.75 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $147.82 | 2023-2025 | Miebo, Infuse, Vyzulta |
| Oyster Point Pharma, INC. | $73.55 | 2024-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $42.90 | 2022 | |
| Abbvie INC. | $32.54 | 2024 | |
| Galderma Laboratories, L.P. | $25.29 | 2023 | |
| Harrow Eye, LLC | $19.32 | 2024 | Vevye |
| Merz Pharmaceuticals, LLC | $16.47 | 2024 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.